In the current study, we sought to improve FGF2 biological activity for its potential use in the regenerative/repair medical settings, such as treatment of burns, chronic wounds, pressure ulcers, diabetic foot, and critical limb ischemia. The gene discussed is FGF2; the disease is decubitus ulcer.